Inhibition of steatosis and liver fibrosis progression in patients with nonalcoholic steatohepatitis and stage two essential hypertension due to the treatment with hepadif, ezetimibe and fosinopril

Please use this identifier to cite or link to this item: http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/25847

Full metadata record

DC Field	Value	Language
dc.contributor.author	Mandryk, O.	-
dc.contributor.author	Yeleniuk, I.	-
dc.contributor.author	Stasiuk, V.	-
dc.date.accessioned	2024-11-06T15:02:46Z	-
dc.date.available	2024-11-06T15:02:46Z	-
dc.date.issued	2021	-
dc.identifier.citation	Results of modern scientific research and development: Proc. of the 3rd Int. sci. and pract. conf. (May 29-31, 2021, Madrid, Spain). Madrid: Barca Academy Publishing, 2021. 675 p.	uk_UA
dc.identifier.uri	http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/25847	-
dc.language.iso	en	uk_UA
dc.subject	nonalcoholic steatohepatitis	uk_UA
dc.subject	SteatoTest	uk_UA
dc.subject	FibroTest	uk_UA
dc.subject	arterial hypertension	uk_UA
dc.title	Inhibition of steatosis and liver fibrosis progression in patients with nonalcoholic steatohepatitis and stage two essential hypertension due to the treatment with hepadif, ezetimibe and fosinopril	uk_UA
dc.type	Thesis	uk_UA
Appears in Collections:	Тези

Files in This Item:

File	Description	Size	Format
Mandryk et al. Inhibition.pdf		337.35 kB	Adobe PDF	View/Open

DSpace JSPUI